Page 41 - Michael Mack News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Storyland Studios announces both the $20,000 grand prize winner and the top three finalists of the first-ever Storyland Design Challenge.

Among the requests are snowplows, mechanics' trucks, a street sweeper, crew cab trucks, tractors, portable radios, riot gear, a water rescue vehicle, a fire marshal vehicle, a dump truck and

There is a different approach to deciding the suitability of TAVR, however

May 17, 2021 Use of apixaban (Eliquis; Bristol-Myers Squibb) following transcatheter aortic valve implantation does not significantly reduce the risk of subclinical valve thrombosis when compared with standard of care, according to a CT substudy from the ATLANTIS trial presented today. However, the results are nuanced, with investigators reporting an intriguing interaction between thrombus risk and prior oral anticoagulation indication. For patients without an indication for oral anticoagulation, use of apixaban as opposed to antiplatelet therapy was associated with a lower risk of subclinic...

email article A direct oral anticoagulant (DOAC) was no better than existing antithrombotic treatments after transcatheter aortic valve replacement (TAVR), according to ATLANTIS trial investigators. TAVR patients randomized to apixaban (Eliquis) instead of antiplatelet therapy or warfarin saw no reduction in the trial's primary endpoint, a composite of death, MI, stroke, systemic emboli, intracardiac or bioprosthesis thrombus, episode of deep vein thrombosis (DVT) or pulmonary embolism (PE), and major bleeding over 1-year follow-up (18.4% vs 20.1%, HR 0.92, 95% CI 0.73-1.16). These find...